Next month will mark an anniversary that Martha Stewart is unlikely to highlight in the monthly calendar of her signature magazine. It has been almost a year since a congressional committee announced that Stewart sold 3,928 shares in ImClone Systems Inc. one day before a devastating Food & Drug Administration ruling sent the stock reeling on Dec. 28. Since then, ImClone CEO Samuel D. Waksal has pleaded guilty and begun settling his insider trading charges, the politicians who publicly pursued Stewart with such fervor have moved on, and there has been little action from investigators at the Justice Dept. and Securities & Exchange Commission.
展开▼
机译：下个月将是玛莎·斯图尔特（Martha Stewart）不太可能在其签名杂志的月历中强调的周年纪念日。国会委员会宣布斯图尔特出售ImClone Systems Inc.的3,928股股票已经过去了将近一年。在此之前，美国食品药品监督管理局（FDA）的一项灾难性裁定于12月28日将股票卷土重来。此后，ImClone首席执行官Samuel D. Waksal拥有了认罪并开始解决他的内幕交易指控，以这种热情公开追捕斯图尔特的政客们继续前进，司法部和证券交易委员会的调查人员几乎没有采取任何行动。
展开▼
